Antibiotic resistance was dominating headlines, with government-backed campaigns urging reduced use and investment in new antibiotics. Amid this conversation, Micreos introduced a radically different approach—an innovative technology – to target MRSA.
The Brief
Micreos, a Dutch biotech company, needed to share breakthrough research quickly and credibly, while opening doors for collaboration with academia and pharma.
Our Approach
With just two weeks to act ahead of a critical meeting, we focused on clarity and resonance—translating highly technical data into a narrative that could be understood and trusted by diverse audiences. By listening to what mattered most to media and stakeholders, we shaped a story that sparked curiosity and confidence.
Strategically briefing select UK, European, and US outlets ahead of launch created momentum. The result? An exclusive front-page lead in The Times, followed by coverage on the Today programme, Sky News, Forbes, Time, Newsweek, and more.
Impact
100+
pieces of quality coverage
107M
media reach
200%
above coverage expectations
This campaign gave us enormous visibility at a time when national strategies to combat infections are being discussed and developed – it has certainly opened new avenues of discussion for us and we are extremely excited about our prospects.
Mark Offerhaus, Micreos CEO
